A reversed-phase high-performance liquid chromatographic method that enables the determination of clonixin in human plasma and urine samples is described. Recovery of the drug was over 87.6 and 80.7% for plasma and urine, respectively. The limit of quantitation of the method was established as 10 ng / ml in plasma and 20 ng / ml in urine samples, with RSDs of less than 11.1%. The applicability of the method was further assessed by determining the plasma concentrations time course of clonixin in six healthy volunteers after single oral dose administration of 150 and 300 mg of clonixin and Clonix.
Introduction
activity in laboratory animals [1] . Analgesic properties have been shown in monkeys [2] and in Clonixin, 2-(3-chloro-o-toluidino) nicotinic acid is humans [3] [4] [5] [6] [7] [8] [9] [10] . Clonixin showed a good safety a nonsteroidal anti-inflammatory drug ( Fig. 1 ) disprofile, with analgesic efficacy, following oral adplaying anti-inflammatory, analgesic and antipyretic ministration of a 600-mg dose, comparable to morphine sulphate 10 mg parenterally [9] . The drug's solubility in aqueous media is very low, with a high trend for partitioning into organic solvents, as revealed by its high octanol / water partition coefficients (unpublished data). Few methods for the assay of clonixin in biological samples have been reported. Katchen and co-workers [11, 12] developed a thin-layer chromatographic method following UV spectrophotometry to study the metabolism and pharmacokinetics of clonixin in rats, dogs and monkeys and in humans, following i.v. and oral administration of 23250 mg gelatine capsules. Clonixin was found to be rapidly *Corresponding author. E-mail address: rcfarinha@mail.telepac.pt (A. Farinha).
absorbed and excreted by humans. The excretion patterns of the parent compound and the urine 2.3. Plasma sample preparation metabolites were very similar between rhesus monkeys and humans.
A 1-ml plasma sample, thawed at room temperaGonzalez-Martin et al. [13] , reported a study of ture, was spiked with 50 ml of a 21.4-mg / ml I.S and the pharmacokinetics of the lysine salt of clonixin in mixed with 50 ml of 6 M hydrochloric acid in a glass 10 children in postoperative care, aged 4-10 years screw-capped tube. To each sample, 4 ml of a old. Serum clonixin concentrations were determined mixture of chloroform-methanol (99.5:0.5) were by a revered-phase high-pressure liquid chromatoadded and the tubes thoroughly mixed for 15 min. graphic method with a limit of quantitation (LOQ) of After centrifugation at 4500 rpm for 5 min, the 100 ng / ml, although further details were not proorganic layer was transferred to a clean glass tube. vided. The pharmacokinetic parameters determined
The remaining aqueous layer was again extracted were different from those previously reported in with additional 4 ml of the chloroform-methanol adult humans and experimental animals.
solution. The organic layer was transferred to the We report here a new specific and sensitive tube containing the first 4 ml organic phase from the method for the determination of clonixin in human previous extraction step. The pooled organic layers plasma and urine samples. The method was applied were evaporated to dryness at 458C under a stream of to a pilot bioavailability study of clonixin in six nitrogen. The dry residue was reconstituted with 100 healthy volunteers.
ml of methanol. Twenty-ml samples were injected into the HPLC apparatus.
Urine sample preparation 2. Experimental
Frozen urine was allowed to thaw at room temperature. The internal standard ( p-chlorowarfarin 2.1. Materials solution at 21.4 mg/ml), 50 ml of 6 M hydrochloric acid, 50 mg of sodium chloride and 4 ml of a Clonixin was a generous gift of Janssen-Cilag mixture of chloroform-methanol (99.5:0.5) were (Amadora, Portugal). p-Chlorowarfarin (internal added to a 1.0-ml urine aliquot in a screw-capped standard, I.S.) was supplied by Aldrich (Madrid, glass tube. The tubes were thoroughly mixed for 15 Spain). All solvents were HPLC grade from E. min. After centrifugation at 4500 rpm for 5 min, the Merck (Darmstadt, Germany). Other reagents were organic layer was transferred to a clean glass tube of analytical-reagent grade, also from E. Merck. and evaporated to dryness under a stream of nitrogen at 458C. The residue was reconstituted with 100 ml 2.2. High-performance liquid chromatography of methanol and 20 ml were injected into the HPLC (HPLC) apparatus.
The HPLC pumping system used in this study was 2.5. Validation study a Merck-Hitachi L-6000A pump. The mobile phase was 28% acetonitrile, 36% methanol and 36% of To assess linearity in plasma samples, two cali-0.3% acetic acid solution at a flow-rate of 1.0 ml / bration curves were prepared. A lower calibration min. Sample injection was performed with a Waters curve ranging from 0.010 to 2.0 mg / ml and a upper 717 Plus autosampler. The HPLC column (25034.0 calibration curve ranging from 0.10 to 26.6 mg / ml. mm I.D.) was a Nucleosil-100, 5-mm C column, A single calibration range was prepared in urine 18 coupled to a mBondapak C guard-column. A from 0.020 to 2.0 mg / ml. Standard samples were 18 Waters 486 UV detector set at 290 nm (0.005 AUFS) prepared by spiking drug-free plasma and urine with was used to monitor the column effluent. A Merckclonixin and the internal standard following extracHitachi D-2500 Chromato-Integrator was used to tion and analysis as described above. The peak acquire and integrate the chromatographic data.
height ratios of clonixin to the internal standard were measured and the calibration curves were obtained had the approval of the clinical unit Ethics Commit-2 by least-squares weighted (1 / conc ) linear regrestee. sion. Regression lines were used to determine clonixin concentrations in the test samples.
2.7. Pharmacokinetic analysis The absolute recovery of clonixin extracted from urine and plasma samples was assessed by comparAll pharmacokinetic parameters were determined ing the peak heights of extracted plasma and urine by non-compartmental models. The slope of the samples, containing known amounts of drug, with terminal log-linear portion of the clonixin concenthose obtained from standard solutions of clonixin, tration versus time profiles was determined by the prepared in methanol-water (1:1), at the same best fit least-squares regression analysis and used as concentration levels. Validation studies also included specificity tests in time to reach C (t ) were taken directly from max max six individual plasma and urine samples, room the observed concentration versus time data. temperature stability, long-term stability and freezethaw stability.
Results and discussion

Application of the plasma method
The chromatograms of blank plasma, spiked plasThe analytical procedure was applied to the analyma with clonixin and internal standard and plasma sis of plasma samples from a pilot pharmacokinetic from a subject dosed with Clonix, are shown in Fig.  and bioavailability study of clonixin, following the 2a-c, respectively. Chromatograms of blank urine administration of Clonix (Janssen-Cilag) 300-mg and urine spiked with clonixin and internal standard immediate release gelatine capsules, from a commerare shown in Fig. 3a,b . No interfering peaks were cially available batch (no. 7G128A; expiry date, July observed at the clonixin retention times. 2000) and two, 150 and 300 mg, in house-prepared
The absolute recovery of clonixin from plasma oral aqueous solutions. Six healthy male volunteers, and urine samples (Table 1) ranged from 87.6 to aged 22-31 years, participated in the clinical in-96.4% and 80.7 to 90.1%, respectively. All calivestigations. None of the subjects had any relevant bration lines showed to be linear over the conmedical history or was on any other medication.
centrations range examined with a r.0.9953. Subjects fasted overnight prior to the administration Tables 2 and 3 include the data obtained for the at 08:00 h. Blood samples were withdrawn until 14 h precision and accuracy. Maximum intra-and interpost-administration and transferred to lithium heparin day precision was 11.06 and 8.07% for plasma and Luer Monovette tubes (Sarstedt, Portugal). The urine, respectively. The accuracy observed for plasresulting plasma (2500 rpm for 10 min, 58C) was ma and urine samples, ranged from 21.67 to stored frozen below 2208C in polypropylene tubes, 10.70% and from 21.90 to 7.68%, respectively. pending analysis. All the subjects gave informed Additional data obtained during the analysis of written consent prior to the start of the study, which plasma samples from the pilot study, showed RSDs 24 h after sample preparation. Long-term stability of stored samples at or below 2208C was assessed by analysing six replicate of 3.22% (n56) and 6.79% (n58), at 16.0 and 26.6 stability samples at a nominal concentration of 0.4 mg / ml, respectively, while accuracy was 1.29% and mg / ml in comparison with daily prepared samples at 20.06%, respectively. The LOQ was defined as the the same concentration level. Plasma samples proved minimum determinable concentration with a relative to be stable for at least 14 weeks (23.4%), while error below 20% [14] . This was 10 ng / ml (RE, urine samples were stable for at least 4 weeks 21.67%) and 20 ng / ml (RE, 21.90%), respectively, (13.5%). These results indicate a good stability of in plasma and urine. This limit of quantification is 10 clonixin in both types of biological matrix. So far, no Fig. 4 shows the mean plasma profiles of clonixin intra-subject RSDs of 15.5 and 18.8%, respectively, (n56) following administration of the three study for AUC and C . 6) represent essentially true experimental values, as idated HPLC method for plasma samples is applicthe mean extrapolated AUC , was 0.01% for both able for the determination of clonixin in human
